Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Wanaka

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Biochemical and Biophysical Research Communications|August 15, 1995
Design of noncovalent trypsin inhibitor based on the X-ray crystal structure of the complexM Nakamura, K Tomoo, T Ishida, et al.
Chemical & Pharmaceutical Bulletin|November 1, 1989
Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikreinY Tsuda, N Teno, Y Okada, et al.
Biological & Pharmaceutical Bulletin|March 26, 1998
Purification method for human plasma kallikrein by a new affinity chromatographyM Tada, K Wanaka, S Okamoto, et al.
Thrombosis Research|April 1, 1996
Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actionsK Wanaka, S Okamoto, N Horie, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2000
Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell linesY Okada, Y Tsuda, K Wanaka, et al.
Leukemia|September 21, 2011
Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitmentM Ishihara, C Nishida, Y Tashiro, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Biochemical and Biophysical Research Communications|August 15, 1995
Design of noncovalent trypsin inhibitor based on the X-ray crystal structure of the complexM Nakamura, K Tomoo, T Ishida, et al.
Chemical & Pharmaceutical Bulletin|November 1, 1989
Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikreinY Tsuda, N Teno, Y Okada, et al.
Biological & Pharmaceutical Bulletin|March 26, 1998
Purification method for human plasma kallikrein by a new affinity chromatographyM Tada, K Wanaka, S Okamoto, et al.
Thrombosis Research|April 1, 1996
Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actionsK Wanaka, S Okamoto, N Horie, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2000
Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell linesY Okada, Y Tsuda, K Wanaka, et al.
Leukemia|September 21, 2011
Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitmentM Ishihara, C Nishida, Y Tashiro, et al.
Pageof 3